The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Cheers, an interesting interview. The disparity of valuation between CNIC and the larger players in the sector is huge - hopefully, as discussed here, CNICs new enlarged scale will bring a re-rating in the share price as well as in profitability.
Especially if CNIC becomes a target for those larger players:
New article - the acquisition will be 44% accretive to EPS per Zeus Capital, who even prior to the acquisition have CNIC on a P/E of only 9.2 (I assume they mean the P/E will reduce further, not increase!):
Https://www.proactiveinvestors.co.uk/companies/news/907393/centralnics-team-internet-acquisition-to-be-44-accretive-to-earnings-in-2020-907393.html
Extract:
"CentralNic’s Team Internet acquisition to be 44% accretive to earnings in 2020
Based in Munich, Team Internet currently runs its operation through over 20mln different domain names serving 35,000 customers
CentralNic Group PLC’s (LON:CNIC) acquisition of German group Team Internet is expected to be nearly 44% accretive to the group’s earnings for its 2020 financial year, according to new analysis from the company’s house broker.
Zeus Capital added in a note published on Monday that the purchase will also be 40.6% accretive in 2021.
WATCH: CentralNic's acquisition of Team Internet to be 'significantly earnings enhancing'
The broker currently has the firm pegged with a price/earnings (PE) ratio of 9.2 for its 2020 financial year, however, this is expected to increase once the acquisition completes next year.
Speaking to Proactive on Monday, CentralNic chief executive Ben Crawford said what makes Team Internet distinct from the rest of its businesses is rather than selling domain names for websites it allows companies to place adverts for themselves of the web pages of defunct competitors, redirecting consumer traffic towards their own sites.
This model means companies can get “the best customer [they] could possibly want”, Crawford says, adding that Team Internet currently runs its operation through over 20mln different domain names serving 35,000 customers.
For CentralNic, the purchase adds another recurring revenue business with organic growth of around 4% per year.
“It’s a business we’ve been chasing for some time”, Crawford says.
etc"